ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Sunday, October 21, 2018

9:00AM-11:00AM
Abstract Number: 670
Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment
9:00AM-11:00AM
Abstract Number: 343
Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice
Measures and Measurement of Healthcare Quality Poster I
9:00AM-11:00AM
Abstract Number: 513
Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 474
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis
9:00AM-11:00AM
Abstract Number: 92
Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 141
Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 88
Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis
Rheumatoid Arthritis – Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 124
M10, a Small Fragment of the Hepatocyte Growth Factor Receptor, Attenuates Fibrotic Changes in a Murine Model of Scleroderma Lung Disease and in Human Lung Fibroblasts
Systemic Sclerosis and Related Disorders – Basic Science Poster I
9:00AM-11:00AM
Abstract Number: 311
Magnetic Resonance Imaging of the Cervical Spine in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Presenting with Chronic Neck Pain – a Systematic Comparison of Clinical Assessments
Imaging of Rheumatic Diseases Poster I: MRI
9:00AM-11:00AM
Abstract Number: 558
Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology
9:00AM-11:00AM
Abstract Number: 162
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa
Antiphospholipid Syndrome Poster
9:00AM-11:00AM
Abstract Number: 519
Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 808
Mean Number of Nailfold Capillaries Is Associated with Disease Activity at 6 Months Follow-up in Systemic Sclerosis Patients
Systemic Sclerosis and Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 635
Measuring Spinal Mobility over Time in Early Axial Spondyloarthritis: Can We Do It Reliably?
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment
9:00AM-11:00AM
Abstract Number: 203
Meat Consumption and Risk of Rheumatoid Arthritis in Women: A Population-Based Cohort Study
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
  • «Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 67
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology